Ronald M Lindsay, Age 771041 Old Marlboro Rd, Concord, MA 01742

6410510, Jun 25, 2002

May 13, 1996

08/645107

Nikos Panayotatos - Orangeburg NY
Keith D. Anderson - Mt. Kisco NY
Stanley J. Wiegand - Ossining NY
Ronald M. Lindsay - Briarcliff Manor NY

Regeneron Pharmaceuticals, Inc. - Tarrytown NY

A61K 3818

514 12, 424 851

Modified ciliary neurotrophic factors and methods for their production and therapeutic use, especially in the treatment of Huntingtons disease.

6933276, Aug 23, 2005

Nov 18, 1994

08/342457

Andreas Hohn - Munich, DE
Yves-Alain Barde - Munich, DE
Hans Thoenen - Munich, DE
Ronald M. Lindsay - Briarcliff Manor NY, US
George Yancopoulos - New York NY, US

Regeneron Pharmaceuticals, Inc. - Tarrytown NY

A61K038/18

514 12, 514866, 514903, 514 2

The present invention relates to neurotrophin-3 (NT-3), a newly discovered member of the BDNF gene family. It is based, in part, on the identification of regions of nucleic acid sequence homology shared by BDNF and NGF (U. S. patent application Ser. No. 07/400,591, filed Aug. 30, 1989, incorporated by reference herein). According to the present invention, these regions of homology may be used to identify new members of the BDNF/NGF gene family; such methodology was used to identify NT-3. The present invention provides for the genes and gene products of new BDNF/NGF related neurotrophic factors identified by these methods. According to the invention, NT-3 may be used in the diagnosis and/or treatment of neurologic disorders, including, but not limited to, Alzheimer's disease and Parkinson's disease. Because NT-3 has been observed to exhibit a spectrum of activity different from the spcificities of BDNF or NGF, NT-3 provides new and valuable options for enducing regrowth and repair in the central nervous system.

5556837, Sep 17, 1996

Aug 1, 1994

8/283700

Eric J. Nestler - Cheshire CT
Melissa T. Berhow - New Haven CT
David S. Russell - Branford CT
Ronald M. Lindsay - Briarcliff Manor NY

Regeneron Pharmaceuticals Inc. - Tarrytown NY
Yale University - New Haven CT

A61K 3817

514 21

The present invention is broadly directed to treatment of an addictive disease or disorder. In particular, the invention relates to inhibiting or reversing the biochemical and neurophysiological changes that correlate with behavioral changes of addictive diseases or disorders. The method of the invention comprises administering to a subject suspected of suffering from an addictive disease or disorder an amount of brain-derived factor (BDNF) or neurotrophin-4 (NT-4), or both, effective to reverse behavioral changes that are associated with the addictive disease or disorder. In a specific Example, administration of BDNF or NT-4 inhibits or reverses increased expression of tyrosine hydroxylase and glial ibrillary acidic protein in the ventral tegmental area of the brain, and inhibits or reverses increased levels of cyclic-AMP-dependent protein kinase activity in the nucleus accumbens.

5512661, Apr 30, 1996

Sep 19, 1994

8/308625

Eric M. Shooter - Portola Valley CA
Ulrich Suter - Menlo Park CA
Nancy P. Ip - Hong Kong, HK
Stephen P. Squinto - Irvington NY
Mark E. Furth - Chapel Hill NC
Ronald M. Lindsay - Briarcliff Manor NY

Regeneron Pharmaceuticals, Inc. - Tarrytown NY

C07K 14475
C07K 1448
C07K 1900

530399

The present invention relates to chimeric neurotrophic factors which comprise at least a portion of a naturally occurring cellular factor and a portion of at least one other molecule such that the resulting chimeric molecule has neurotrophic activity. It is based, in part, on the discovery that chimeric molecules comprising portions of both NGF and BDNF are likely to possess neurotrotrophic activity, and in some cases exhibit a spectrum of activity larger than that of either parent molecule. It is further based on the discovery that chimeric molecules comprising neurotrophic factor sequences as well as additional peptide sequences may retain neurotrophic activity, and in some cases may exhibit a more potent activity than the parent factor. The chimeric neurotrophic factor molecules of the invention provide a number of advantages relative to naturally occurring neurotrophic factors. Chimeric neurotrophic factors may be used to provide, for example, the activity of two neurotrophic factors in a single molecule, or may serve as superagonists of an endogenous neurotrophic factor, thereby enabling an increased biological response at lower doses.

5827823, Oct 27, 1998

Jan 25, 1995

8/378079

Judith Siuciak - Tarrytown NY
Charles A. Altar - Katonah NY
Ronald M. Lindsay - Briarcliff Manor NY

Regeneron Pharmaceuticals, Inc. - Tarrytown NY

A61K 3810
A61K 3530

514 12

Infusions of brain-derived neurotrophic factor, neurotrophin-3 or neurotrophin-4 are used to produce analgesia in mammals. In addition, these neurotrophins are used to treat other diseases or disorders mediated by serotonin.

5169764, Dec 8, 1992

Aug 8, 1990

7/564929

Eric M. Shooter - Portola Valley CA
Ulrich Suter - Menlo Park CA
Nancy Ip - Stamford CT
Stephen P. Squinto - Irvington NY
Mark E. Furth - Pelham NY
Ronald M. Lindsay - Briarcliff Manor NY
George D. Yancopoulos - Briarcliff Manor NY

Regeneron Pharmaceuticals, Inc. - Tarrytown NY

C12P 2102
C12N 1518
C07H 1702
C07K 1300

435 697

The present invention relates to chimeric neurotrophic factors which comprise at least a portion of a naturally occurring cellular factor and a portion of at least one other molecule such that the resulting chimeric molecule has neurotrophic activity. It is based, in part, on the discovery that chimeric molecules comprising portions of both NGF and BDNF are likely to possess neurotrotrophic activity, and in some cases exhibit a spectrum of activity larger than that of either parent molecule. It is further based on the discovery that chimeric molecules comprising neurotrophic factor sequences as well as additional peptide sequences may retain neurotrophic activity, and in some cases may exhibit a more potent activity than the parent factor. The chimeric neurotrophic factor molecules of the invention provide a number of advantages relative to naturally occurring neurotrophic factors. Chimeric neurotrophic factors may be used to provide, for example, the activity of two neurotrophic factors in a single molecule, or may serve as superagonists of an endogenous neurotrophic factor, thereby enabling an increased biological response at lower doses.

2018029, Oct 18, 2018

Dec 1, 2015

15/531224

- LA JOLLA CA, US
Richard A. Lerner - La Jolla CA, US
Ronald M. Lindsay - Concord MA, US

C07K 1/04
C07K 14/64
C07K 14/59
C07K 14/575
C07K 16/26

The present invention provides methods for generating functional derivatives of effector polypeptides (e.g., hormones and receptor ligands) embedded in a different protein scaffold (e.g., antibody scaffolds). The methods involve modifying the effector polypeptide with a combinatorial library of terminal linker sequences, inserting the modified sequences into the host scaffold, and then selecting functional derivatives from the library of modified polypeptide sequences embedded in the host scaffold. As exemplifications, the invention also provides specific functional derivatives of leptin, scFSH and scRelaxin embedded in an antibody scaffold, as well as therapeutic applications of such functional fusion molecules.